Gallbladder, pancreatitis and other risks on GLP-1

Most GLP-1 medication side effects are gastrointestinal and self-limiting. A handful are more serious. This article covers the ones we specifically screen for and monitor, because knowing how to recognise them early matters.

Gallstones

Why they happen on GLP-1 medication: rapid weight loss is a well-established cause of gallstone formation. This is true of any weight-loss method, including bariatric surgery, and is not specific to GLP-1 drugs. When the body mobilises fat stores quickly, the liver processes more cholesterol and some of it crystallises in the bile.

How common: approximately 1-2 percent of patients in the large GLP-1 trials developed symptomatic gallstones. The risk is higher in patients losing weight quickly (more than 1.5 percent of body weight per week), in women, and in patients with a family history.

What you might notice:

Right-upper-quadrant abdominal pain, particularly after fatty meals.

Pain radiating to the right shoulder blade.

Nausea and vomiting (distinguishable from GLP-1 nausea because it is sharp and localised rather than diffuse).

Jaundice (yellow skin/eyes) if a stone blocks the bile duct.

Fever plus abdominal pain suggests cholecystitis (gallbladder inflammation) and is an A&E situation.

What we do:

Pre-treatment: ask about previous gallstone history and any abdominal symptoms. Consider a baseline ultrasound if your pre-treatment BMI is very high or you have a family history.

During treatment: if you report right-upper-quadrant pain, we arrange ultrasound.

Prophylaxis: for patients losing weight rapidly who have gallstone risk factors, we may prescribe ursodeoxycholic acid 300mg twice daily to reduce stone formation. This is evidence-based and well tolerated.

If stones develop: treatment depends on severity. Many resolve with medication. Symptomatic stones requiring gallbladder removal (cholecystectomy) are usually done as day-case laparoscopic surgery.

Pancreatitis

The bigger clinical concern. Pancreatitis (inflammation of the pancreas) is a rare but serious complication of GLP-1 medication.

How common: large studies have shown a small increase in pancreatitis risk compared with non-GLP-1 weight loss approaches. The absolute risk is low, roughly 0.2 to 0.5 percent over a year of treatment, but pancreatitis can be severe.

Risk factors for pancreatitis on GLP-1:

Personal history of pancreatitis (we do not prescribe if this applies).

Heavy alcohol use.

Gallstones (hence the connection between the two risks).

High triglycerides.

Some medications (corticosteroids, azathioprine, valproate).

What you might notice:

Severe central or upper-abdominal pain, typically radiating to the back.

Nausea and vomiting that will not settle.

Pain worsens with eating.

Pain often described as "the worst I have ever had" or knife-like.

Fever can occur.

This is an A&E presentation. Do not message us first. Go to A&E. Mention you are on GLP-1 medication so they can check amylase/lipase promptly.

How we reduce risk:

Screen for all the above risk factors before starting.

Advise against heavy alcohol during treatment.

Recommend triglyceride checks annually.

Stop the medication immediately if any episode of unexplained severe abdominal pain occurs.

If you have had a pancreatitis episode related to GLP-1 medication, we will not restart the drug.

Thyroid C-cell tumours (medullary thyroid cancer)

The rat signal. In rat studies, high-dose GLP-1 medications caused medullary thyroid cancer. This has not been demonstrated in humans despite extensive monitoring over the last decade.

However, the theoretical concern has shaped prescribing:

Do not prescribe in patients with personal or family history of medullary thyroid cancer.

Do not prescribe in patients with multiple endocrine neoplasia type 2 (MEN2), a genetic condition predisposing to these tumours.

What we do: ask about personal and family history of thyroid cancer at assessment. We do not screen with calcitonin or ultrasound in the general population because the evidence for this approach is limited.

Diabetic retinopathy worsening

Relevant to patients with type 2 diabetes. Rapid improvement in blood glucose control can cause temporary worsening of existing diabetic retinopathy. This is not a GLP-1-specific issue; any rapid glycaemic improvement can do it.

What we do: in patients with known retinopathy, check with an ophthalmologist before starting or soon after. Slow the titration if retinopathy is active. Most cases are temporary; the long-term benefit of glycaemic control outweighs the short-term retinopathy risk.

Kidney injury

Rare and usually context-dependent. Usually seen in patients who have become severely dehydrated from vomiting or severe diarrhoea. Kidney function returns to normal with fluid correction.

What we do: kidney function on the biannual blood panel. If it drops, investigate dehydration first, then consider other causes.

Gastroparesis (severe gastric stasis)

Rare but occasionally reported. GLP-1 medications slow gastric emptying; this is how they work. In rare cases this effect becomes extreme, with food sitting in the stomach for days and causing severe symptoms.

What you might notice:

Persistent fullness even between meals.

Severe, ongoing nausea not settling after several weeks.

Vomiting hours after eating.

Feeling "blocked" at the top of the stomach.

What we do: if these symptoms persist despite dose reduction, we stop the medication and arrange gastric-emptying assessment if needed. Gastroparesis is usually reversible on stopping.

Less serious but worth noting

Increased heart rate (average 2-4 bpm rise) during treatment.

Modest rise in amylase/lipase on blood tests (often without pancreatitis).

Small rise in liver enzymes on blood tests (rarely clinically significant).

We monitor all of these on blood tests and act on them if they are out of range or trending significantly.

The honest summary

The serious risks of GLP-1 medication are real but uncommon. For most patients who meet the prescribing criteria, the benefits substantially outweigh the risks. Careful screening before prescribing, and prompt response to concerning symptoms during treatment, keeps the absolute risk very low.

If you develop severe abdominal pain, especially radiating to the back, go to A&E. Do not wait for a message reply.

Ready to start?

If this article has made you think medication might help, the next step is a short consultation with one of our weight-management doctors.

Begin your consultation at this link. Online in 30 minutes, or in person at Westfield London.